IDEXX Laboratories Inc (IDXX) KPIs and segments
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của IDEXX Laboratories · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của IDEXX Laboratories: 45 chỉ số vận hành, trong đó có Total Premium Instrument Placements — Worldwide, Global Active Premium Analyzer Installed Base và U.S. Companion Animal Veterinary Practice Trends, lấy từ 284 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CAG segment revenue($M) | 1,118 | 1,054 | 998 | 1,013 | 1,022 | 920 | 870 | 892 | 922 | 889 | 821 | ||
Water segment revenue($M) | 58.6 | 50.3 | 50.5 | 54.3 | 51.0 | 45.3 | 45.2 | 50.2 | 46.7 | 43.1 | 41.8 | ||
LPD($M) | 35.2 | 32.5 | 37.5 | 33.9 | 31.8 | 28.6 | 34.6 | 29.0 | 30.3 | 28.2 | 32.8 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
CAG Diagnostics Recurring Revenue($M) | 975 | 920 | 850 | 873 | 878 | 806 | 757 | 783 | 808 | 780 | 712 | ||
Product revenue($M) | 719 | 666 | 652 | 656 | 658 | 573 | 560 | 568 | 577 | 543 | 522 | ||
Service revenue($M) | 498 | 475 | 438 | 449 | 452 | 425 | 394 | 408 | 426 | 421 | 380 | ||
IDEXX Vetlab Consumables($M) | 430 | 413 | 389 | 388 | 375 | 345 | 332 | 329 | 325 | 317 | 297 | ||
Reference Laboratory Diagnostic And Consulting Services($M) | 407 | 386 | 349 | 363 | 368 | 344 | 316 | 328 | 347 | 344 | 305 | ||
Rapid Assay Products($M) | 102 | 84.9 | 76.0 | 88.6 | 100 | 84.0 | 77.4 | 92.8 | 103 | 86.3 | 77.6 | ||
Veterinary Software, Services and Diagnostic Imaging Systems($M) | 96.3 | 91.3 | 90.7 | 87.8 | 85.8 | 81.6 | 80.0 | 79.0 | 78.6 | 75.0 | 71.0 | ||
Recurring revenue($M) | 76.3 | 73.5 | 70.6 | 71.0 | 69.0 | 65.8 | 62.9 | 64.6 | 63.1 | 59.7 | 54.6 | ||
CAG Diagnostic Capital - Instruments($M) | 47.2 | 42.4 | 58.1 | 51.5 | 58.6 | 32.0 | 33.0 | 29.5 | 35.3 | 34.1 | 38.2 | ||
CAG Diagnostics Service And Accessories($M) | 36.1 | 36.6 | 35.3 | 34.1 | 34.9 | 33.0 | 32.2 | 33.2 | 32.4 | 32.6 | 32.1 | ||
Systems and hardware($M) | 20.0 | 17.8 | 20.1 | 16.8 | 16.9 | 15.8 | 17.1 | 14.4 | 15.4 | 15.3 | 16.5 | ||
United States($M) | 773 | 725 | 675 | 705 | 718 | 655 | 604 | 638 | 660 | 631 | 576 | ||
Europe, the Middle East and Africa($M) | 266 | 257 | 254 | 245 | 233 | 205 | 208 | 199 | 201 | 200 | 184 | ||
Asia Pacific($M) | 101 | 94.4 | 94.2 | 90.7 | 89.3 | 81.7 | 83.3 | 81.0 | 80.4 | 76.3 | 82.4 | ||
Canada($M) | 50.8 | 40.9 | 42.0 | 41.4 | 46.7 | 37.3 | 38.3 | 36.9 | 41.0 | 36.7 | 36.9 | ||
Latin America & Caribbean($M) | 25.8 | 23.2 | 23.0 | 22.3 | 20.0 | 21.0 | 21.3 | 20.2 | |||||
CAG segment revenue($M) | 716 | 668 | 604 | 627 | 642 | 575 | 519 | 544 | 569 | 546 | |||
Water segment revenue($M) | 43.6 | 36.5 | 33.6 | 38.1 | 35.5 | 32.1 | 32.7 | 34.8 | 32.1 | 30.5 | |||
LPD($M) | 18.7 | 16.9 | 19.0 | 15.9 | 14.9 | 14.4 | 17.1 | 14.6 | 15.6 | 15.2 | |||
Product revenue($M) | 514 | 472 | 435 | 449 | 452 | 398 | 377 | 392 | 397 | 366 | 336 | ||
Service revenue($M) | 265 | 251 | 223 | 234 | 242 | 226 | 193 | 204 | 223 | 227 | 190 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4 | |||||||||||||
Total Premium Instrument Placements — Worldwide6 | 5,780 | 5,265 | 4,650 | 6,567 | 5,665 | 6,070 | 4,163 | 4,625 | 4,128 | 4,952 | 4,791 | 5,241 | |
Catalyst Chemistry Analyzer Placements — Worldwide4 | 1,475 | 1,343 | 1,360 | 1,776 | 1,577 | 1,413 | 1,469 | 1,765 | 1,612 | 1,894 | 1,668 | 2,191 | |
Catalyst New & Competitive Placements — Worldwide2 | 1,162 | 1,008 | 1,015 | 1,369 | 1,203 | 1,091 | 1,108 | 1,269 | 1,153 | 1,295 | 1,150 | 1,469 | |
Catalyst Second-Analyzer Placements — Worldwide2 | 313 | 334 | 345 | 407 | 374 | 322 | 361 | 498 | 445 | 560 | 443 | 590 | |
Catalyst Placements — U.S. | 470 | 473 | 481 | 597 | 554 | 530 | 530 | 685 | 570 | 690 | 570 | 787 | |
Catalyst Placements — International | 1,005 | 870 | 879 | 1,179 | 1,023 | 883 | 939 | 1,080 | 1,042 | 1,204 | 1,098 | 1,404 | |
Premium Hematology Analyzer Placements — Worldwide4 | 1,418 | 1,402 | 1,430 | 1,860 | 1,601 | 1,525 | 1,597 | 1,950 | 1,678 | 2,198 | 2,361 | 2,205 | |
Premium Hematology New & Competitive — Worldwide2 | 1,161 | 1,067 | 1,138 | 1,450 | 1,328 | 1,223 | 1,250 | 1,466 | 1,181 | 1,312 | 1,207 | 1,440 | |
Premium Hematology Upgrades — Worldwide2 | 257 | 335 | 292 | 273 | 302 | 347 | 497 | 886 | 1,154 | ||||
Premium Hematology Placements — U.S. | 393 | 403 | 387 | 500 | 462 | 450 | 441 | 518 | 486 | 581 | 522 | 694 | |
Premium Hematology Placements — International | 1,025 | 999 | 1,043 | 1,360 | 1,139 | 1,075 | 1,156 | 1,432 | 1,192 | 1,617 | 1,839 | 1,511 | |
IDEXX inVue Dx Cellular Analyzer Placements — Worldwide2 | 1,904 | 1,602 | 1,099 | 1,940 | 1,753 | 2,388 | 302 | ||||||
IDEXX inVue Dx Placements — U.S. | 970 | 932 | 638 | 1,216 | 1,196 | 1,829 | 285 | ||||||
IDEXX inVue Dx Placements — International | 934 | 670 | 461 | 724 | 557 | 559 | 17 | ||||||
SediVue Dx Urine Sediment Analyzer Placements — Worldwide2 | 983 | 918 | 761 | 991 | 734 | 744 | 795 | 900 | 838 | 860 | 762 | 845 | |
SediVue Dx Placements — U.S. | 349 | 343 | 266 | 354 | 300 | 270 | 288 | 362 | 336 | 361 | 284 | 353 | |
SediVue Dx Placements — International | 634 | 575 | 495 | 637 | 434 | 474 | 507 | 538 | 502 | 499 | 478 | 492 | |
Total Premium Instrument Placements — U.S. | 2,182 | 2,151 | 1,772 | 2,667 | 2,512 | 3,079 | 1,544 | 1,575 | 1,392 | 1,632 | 1,376 | 1,834 | |
Total Premium Instrument Placements — International | 3,598 | 3,114 | 2,878 | 3,900 | 3,153 | 2,991 | 2,619 | 3,050 | 2,736 | 3,320 | 3,415 | 3,407 | |
Global Active Premium Analyzer Installed Base (Thousands of Units)5 | |||||||||||||
Catalyst Chemistry Analyzer Installed Base (k units)1 | 80.60 | 79.80 | 78.80 | 77.90 | 76.70 | 75.80 | 78.80 | 74.10 | 72.90 | 71.70 | 75.10 | 69.10 | |
Catalyst Installed Base YoY Growth(%) | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% | 6.0% | 7.0% | 8.0% | 9.0% | 10.0% | |||
Premium Hematology Analyzer Installed Base (k units)1 | 58.60 | 57.80 | 56.90 | 55.90 | 54.60 | 53.70 | 56.90 | 51.80 | 50.80 | 49.90 | 52.80 | 47.80 | |
Premium Hematology Installed Base YoY Growth(%) | 7.0% | 8.0% | 8.0% | 17.0% | 8.0% | 10.0% | 11.0% | ||||||
SediVue Dx Analyzer Installed Base (k units)1 | 26.40 | 25.70 | 24.80 | 24.30 | 23.30 | 22.70 | 24.80 | 21.30 | 20.40 | 19.60 | 22.00 | 18.10 | |
SediVue Dx Installed Base YoY Growth(%) | 13.0% | 13.0% | 13.0% | 17.0% | 14.0% | 15.0% | 17.0% | 18.0% | 17.0% | 16.0% | |||
IDEXX inVue Dx Analyzer Installed Base (k units) | 11.00 | 9.10 | 7.50 | 6.40 | 4.50 | 2.70 | 7.50 | 6.40 | 0.30 | ||||
Total Global Premium Instrument Installed Base YoY Growth(%) | 11.0% | 11.0% | 12.0% | 12.0% | 10.0% | 10.0% | 9.0% | 9.0% | 10.0% | 11.0% | 11.0% | 11.0% | |
U.S. Companion Animal Veterinary Practice Trends (IDEXX Practice Intelligence)5 | |||||||||||||
U.S. Same-Store Practice Total Revenue YoY Growth(%) | 2.4% | 3.5% | 3.9% | 3.0% | 3.3% | 1.6% | 2.1% | 2.0% | 3.0% | 3.4% | 3.3% | 5.2% | |
U.S. Same-Store Practice Total Visits YoY Growth(%) | -3.2% | -2.3% | -1.9% | -2.6% | -2.1% | -3.6% | -3.2% | -2.7% | -2.0% | -2.1% | -2.4% | -0.7% | |
U.S. Same-Store Clinical Visits YoY Growth(%)2 | -1.8% | -1.0% | -0.7% | -1.6% | -0.9% | -2.5% | -2.7% | -2.7% | -1.8% | -1.5% | -2.1% | -0.1% | |
U.S. Non-Wellness Clinical Visits YoY Growth(%) | -0.6% | 0.5% | 0.8% | 0.0% | 0.3% | -2.5% | -2.4% | -1.3% | -0.6% | -0.7% | -1.8% | 0.2% | |
U.S. Wellness Clinical Visits YoY Growth(%) | -3.5% | -3.3% | -3.2% | -4.3% | -2.8% | -2.4% | -3.1% | -5.0% | -3.6% | -2.6% | -2.7% | -0.6% | |
U.S. Companion Animal Diagnostic Revenue per Practice YoY Growth(%)3 | 5.5% | 6.0% | 6.5% | 6.5% | 6.5% | 5.0% | 4.5% | 4.0% | 3.5% | 5.0% | 5.0% | 7.0% | |
Clinical Visit Growth Contribution(%) | -2.0% | -1.5% | -1.0% | -1.5% | -1.0% | -2.0% | -2.5% | -2.5% | -2.0% | -2.0% | -2.5% | -0.5% | |
Diagnostic Frequency Contribution (% of Clinical Visits Including Dx)(%) | 0.5% | 0.5% | 1.0% | 1.0% | 0.5% | 0.5% | 0.5% | 0.0% | -0.5% | -0.5% | 0.0% | 0.0% | |
Diagnostic Utilization Contribution (Dx Revenue $ per Clinical Visit Including Dx)(%) | 7.0% | 7.0% | 6.5% | 7.0% | 7.0% | 6.5% | 6.5% | 6.5% | 6.0% | 7.5% | 7.5% | 7.5% | |
IDEXX U.S. CAG Diagnostics Recurring Growth Premium vs. U.S. Clinical Visits(bps) | 1,100 | 1,100 | 1,100 | 1,100 | 950 | 800 | 900 | ||||||
Companion Animal Group (CAG) Total Revenue($M)8 | 1,116 | 1,118 | 1,054 | 999 | 1,013 | 1,022 | 920 | 871 | 892 | 922 | 889 | 821 | |
CAG Diagnostics Recurring Revenue($M)10 | 967 | 975 | 920 | 850 | 873 | 878 | 806 | 758 | 783 | 809 | 780 | 712 | |
CAG Diagnostics Recurring Organic Growth(%) | 11.0% | 10.3% | 11.0% | 10.2% | 10.1% | 7.4% | 4.5% | 6.6% | 9.8% | ||||
CAG Diagnostics Recurring Global Net Price Realization(%) | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | ||||||||
CAG Diagnostics Recurring Reported Growth(%) | 10.8% | 11.0% | 14.1% | 12.2% | 11.5% | 8.6% | 3.3% | 6.4% | 10.8% | ||||
CAG Diagnostics Recurring Currency Impact(%) | -0.2% | 0.7% | 3.1% | 1.9% | 1.3% | 1.2% | -1.2% | -0.2% | 1.0% | ||||
CAG Diagnostics Recurring Revenue — U.S.($M)2 | 620 | 631 | 595 | 537 | 566 | 575 | 537 | 490 | 523 | 545 | 523 | 471 | |
U.S. CAG Diagnostics Recurring Organic Growth(%) | 9.6% | 9.7% | 10.7% | 9.5% | 8.3% | 5.6% | 2.7% | 4.1% | 8.9% | ||||
U.S. CAG Diagnostics Recurring Reported Growth(%) | 9.6% | 9.7% | 10.7% | 9.5% | 8.3% | 5.6% | 2.7% | 4.1% | 8.9% | ||||
CAG Diagnostics Recurring Revenue — International($M)3 | 347 | 344 | 326 | 313 | 307 | 303 | 269 | 267 | 261 | 264 | 257 | 241 | |
International CAG Diagnostics Recurring Organic Growth(%) | 13.6% | 11.6% | 11.7% | 11.5% | 13.6% | 10.9% | 8.5% | 11.6% | 11.6% | ||||
International CAG Diagnostics Recurring Reported Growth(%) | 12.9% | 13.6% | 21.0% | 17.1% | 17.8% | 14.8% | 4.7% | 10.8% | 14.7% | ||||
International CAG Diagnostics Recurring Currency Impact(%) | -0.7% | 2.0% | 9.3% | 5.6% | 4.2% | 3.9% | -3.7% | -0.8% | 3.1% | ||||
IDEXX VetLab Consumables Revenue($M)3 | 443 | 430 | 413 | 389 | 388 | 375 | 345 | 332 | 329 | 325 | 317 | 297 | |
VetLab Consumables Organic Growth(%) | 14.6% | 13.6% | 15.4% | 14.7% | 15.9% | 13.6% | 10.5% | 11.8% | 12.5% | ||||
VetLab Consumables Reported Growth(%) | 14.3% | 14.7% | 19.7% | 17.2% | 17.8% | 15.3% | 8.8% | 11.6% | 13.9% | ||||
VetLab Consumables Currency Impact(%) | -0.3% | 1.1% | 4.2% | 2.5% | 1.9% | 1.7% | -1.7% | -0.2% | 1.4% | ||||
Reference Laboratory Diagnostic & Consulting Services Revenue($M)3 | 399 | 407 | 386 | 349 | 363 | 368 | 344 | 316 | 328 | 347 | 344 | 305 | |
Reference Laboratory Organic Growth(%) | 10.2% | 10.3% | 9.7% | 8.9% | 9.4% | 4.8% | 0.9% | 3.8% | 6.9% | ||||
Reference Laboratory Reported Growth(%) | 10.0% | 10.6% | 12.1% | 10.5% | 10.5% | 5.9% | 0.0% | 3.6% | 7.7% | ||||
Reference Laboratory Currency Impact(%) | -0.2% | 0.3% | 2.5% | 1.6% | 1.1% | 1.1% | -0.8% | -0.2% | 0.8% | ||||
Rapid Assay Products Revenue($M)3 | 89.1 | 102 | 84.9 | 76 | 88.6 | 100 | 84 | 77.4 | 92.8 | 103 | 86.3 | 77.6 | |
Rapid Assay Organic Growth(%) | 0.7% | 1.1% | -0.1% | -2.5% | -5.0% | -3.3% | -1.9% | 0.2% | 8.5% | ||||
Rapid Assay Reported Growth(%) | 0.6% | 1.3% | 1.1% | -1.7% | -4.5% | -3.0% | -2.6% | -0.2% | 9.0% | ||||
Rapid Assay Currency Impact(%) | -0.2% | 0.3% | 1.2% | 0.8% | 0.5% | 0.4% | -0.7% | -0.4% | 0.5% | ||||
CAG Diagnostics Services & Accessories Revenue($M)3 | 35.9 | 36.1 | 36.6 | 35.3 | 34.1 | 34.9 | 33 | 32.2 | 33.2 | 32.4 | 32.6 | 32.1 | |
CAG Services & Accessories Organic Growth(%) | 5.4% | 2.1% | 7.2% | 7.5% | 1.3% | 6.0% | 3.0% | 0.6% | 17.1% | ||||
CAG Services & Accessories Reported Growth(%) | 5.3% | 3.2% | 10.8% | 9.7% | 2.8% | 7.7% | 1.5% | 0.3% | 18.3% | ||||
CAG Services & Accessories Currency Impact(%) | -0.1% | 1.1% | 3.6% | 2.2% | 1.5% | 1.7% | -1.5% | -0.3% | 1.3% | ||||
CAG Diagnostics Capital — Instruments Revenue($M)3 | 51.5 | 47.2 | 42.4 | 58.1 | 51.5 | 58.6 | 32 | 33 | 29.5 | 35.3 | 34.1 | 38.2 | |
CAG Capital Instruments Organic Growth(%) | 0.4% | -19.6% | 28.0% | 69.2% | 70.7% | 62.5% | -4.6% | -11.9% | -2.8% | ||||
CAG Capital Instruments Reported Growth(%) | 0.0% | -19.5% | 32.7% | 76.1% | 74.3% | 66.0% | -6.2% | -13.5% | -2.0% | ||||
CAG Capital Instruments Currency Impact(%) | -0.3% | 0.1% | 4.7% | 6.8% | 3.6% | 3.5% | -1.5% | -1.6% | 0.9% | ||||
Veterinary Software, Services & Diagnostic Imaging Systems Revenue($M)5 | 97.1 | 96.3 | 91.3 | 90.7 | 87.8 | 85.8 | 81.6 | 80 | 79 | 78.6 | 75 | 71 | |
Veterinary Software & Imaging Organic Growth(%) | 9.9% | 11.8% | 10.9% | 13.0% | 11.0% | 9.2% | 7.5% | 7.2% | 6.1% | ||||
Veterinary Software & Imaging Reported Growth(%) | 10.6% | 12.2% | 11.9% | 13.3% | 11.1% | 9.3% | 8.7% | 12.6% | 6.2% | ||||
Veterinary Software & Imaging Acquisitions Impact(%) | 0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 5.6% | 0.0% | ||||
Veterinary Software, Services & Imaging — Recurring Revenue($M)2 | 77.5 | 76.3 | 73.5 | 70.6 | 71 | 69 | 65.8 | 62.9 | 64.6 | 63.1 | 59.7 | 54.6 | |
Veterinary Software Recurring Organic Growth(%) | 8.2% | 10.2% | 10.7% | 11.9% | 9.7% | 9.1% | 9.0% | 8.5% | 12.0% | ||||
Veterinary Software Recurring Reported Growth(%) | 9.1% | 10.7% | 11.8% | 12.2% | 9.8% | 9.2% | 10.2% | 15.3% | 12.1% | ||||
Veterinary Software, Services & Imaging — Systems & Hardware Revenue($M)2 | 19.7 | 20 | 17.8 | 20.1 | 16.8 | 16.9 | 15.8 | 17.1 | 14.4 | 15.4 | 15.3 | 16.5 | |
Veterinary Software & Imaging Hardware Organic Growth(%) | 17.0% | 18.2% | 12.0% | 17.2% | 16.9% | 9.4% | 1.6% | 2.9% | -9.5% | ||||
Veterinary Software & Imaging Hardware Reported Growth(%) | 17.0% | 18.4% | 12.5% | 17.3% | 16.8% | 9.5% | 2.8% | 3.9% | -9.6% | ||||
CAG Segment Organic Revenue Growth(%) | 10.4% | 8.7% | 11.6% | 12.8% | 12.2% | 9.7% | 4.4% | 5.8% | 8.8% | ||||
CAG Segment Reported Revenue Growth(%) | 10.2% | 9.4% | 14.6% | 14.7% | 13.5% | 10.9% | 3.4% | 6.0% | 9.7% | ||||
CAG Segment Currency Impact(%) | -0.2% | 0.6% | 3.0% | 1.9% | 1.3% | 1.2% | -1.1% | -0.3% | 0.9% | ||||
CAG Segment Revenue — U.S.($M)2 | 726 | 735 | 691 | 643 | 668 | 685 | 624 | 574 | 604 | 629 | 602 | 550 | |
CAG Segment Revenue — International($M)3 | 390 | 383 | 363 | 356 | 344 | 338 | 296 | 296 | 288 | 294 | 287 | 272 | |
Remaining Performance Obligations — Multi-Year Customer Commitment Arrangements($M) | 5,300 | 5,300 | 4,900 | 5,000 | 4,700 | 4,700 | 4,700 | 4,400 | 4,200 | 4,100 | 3,900 | 3,800 | |
Remaining Performance Obligations — Reagent Rental Arrangements($M) | 139 | 112 | 102 | 94.7 | 75.6 | 72.3 | 69.1 | 69.1 | 72.1 | 64 | 59.9 | 56.4 | |
Remaining Performance Obligations — Extended Warranties (>1 Year)($M) | 10.1 | 9.70 | 9.40 | 9.50 | 9 | 9.10 | 8.80 | 8.70 | 9.10 | 9.10 | 9.50 | 9.70 | |
Contract Assets under Customer Commitment Arrangements($M)2 | 349 | 333 | 319 | 313 | 289 | 275 | 253 | 246 | 247 | 239 | 230 | 223 | |
Contract Assets — Current($M) | 85.7 | 82.3 | 77.7 | 75.8 | 72 | 67.9 | 62.9 | 60.8 | 61.4 | 58.7 | 56.6 | 55.1 | |
Contract Assets — Noncurrent($M) | 263 | 250 | 241 | 237 | 217 | 207 | 190 | 186 | 186 | 180 | 173 | 168 | |
Capitalized Upfront Customer Incentives & IDEXX Points($M)2 | 277 | 272 | 265 | 250 | 237 | 218 | 198 | 197 | 189 | 192 | 168 | ||
Capitalized Customer Incentives — Current($M) | 83 | 80.1 | 76.9 | 73.6 | 70 | 66.7 | 62.2 | 61.7 | 58.5 | 59.6 | 54.5 | 54.1 | |
Capitalized Customer Incentives — Noncurrent($M) | 194 | 192 | 188 | 177 | 167 | 151 | 136 | 135 | 130 | 132 | 114 | 115 | |
Contract Liabilities & Deferred Extended Warranty / Software PCS Revenue3 | |||||||||||||
Contract Liabilities (Deferred Revenue) — Current($M) | 40.2 | 36.4 | 36.3 | 35.3 | 35.7 | 36.3 | 35 | 33.8 | 38.4 | 38 | 38.2 | 37.2 | |
Contract Liabilities (Deferred Revenue) — Noncurrent($M) | 32.7 | 32.6 | 32.3 | 32.2 | 31.1 | 31.8 | 26.8 | 26.9 | 26.8 | 26.8 | 28 | 28.5 | |
Deferred Extended Warranty & Software Post-Contract Support Revenue($M) | 27.6 | 27.4 | 27.3 | 27.1 | 26.3 | 26.3 | 25.8 | 25.2 | 25.8 | 25.7 | 26 | 26 | |
Capitalized Incremental Customer Commitment Sales Commissions($M) | 20.9 | 21.1 | 21.3 | 21.4 | 21.5 | 21.5 | 22.8 | 22 | 20.6 | 19.6 | 19.7 | 19.7 | |
Reagent Rental & Instrument Lease Economics2 | |||||||||||||
Instrument Rental & Reagent Rental Lease Revenue($M) | 5.80 | 3.90 | 3.80 | 4 | 4.80 | 3.70 | 3.30 | 3.30 | 3.50 | 3.30 | 3.80 | 5.40 | |
Sales-Type Reagent Rental Lease Receivables($M) | 20.7 | 17.5 | 17.5 | 18 | 18.2 | 18.6 | 18 | 19 | 21.2 | 20.4 | 21.8 | 23.1 | |
CAG Segment Gross Profit & Operating Income2 | |||||||||||||
CAG Segment Gross Profit($M)1 | 701 | 716 | 668 | 604 | 628 | 642 | 575 | 519 | 545 | 569 | 546 | ||
CAG Segment Gross Margin(%) | 62.8% | 64.0% | 63.3% | 62.0% | 62.8% | 62.5% | 61.0% | 61.7% | 61.4% | ||||
CAG Segment Operating Income($M)1 | 370 | 393 | 338 | 329 | 349 | 295 | 277 | 242 | 280 | 222 | |||
CAG Segment Operating Margin(%) | 33.1% | 35.2% | 32.0% | 32.4% | 34.1% | 32.1% | 31.1% | 26.2% | 31.5% | ||||
Water Microbiology Testing Segment Revenue($M)7 | 58.8 | 58.6 | 50.3 | 50.5 | 54.3 | 51 | 45.3 | 45.2 | 50.2 | 46.7 | 43.1 | 41.8 | |
Water Segment Organic Revenue Growth(%) | 7.8% | 13.0% | 7.1% | 9.5% | 7.0% | 8.4% | 7.3% | 9.0% | 5.1% | ||||
Water Segment Reported Revenue Growth(%) | 8.4% | 14.8% | 10.9% | 11.9% | 8.2% | 9.1% | 5.2% | 8.1% | 6.3% | ||||
Water Segment Currency Impact(%) | 0.6% | 1.9% | 3.8% | 2.4% | 1.2% | 0.8% | -2.1% | -0.9% | 1.2% | ||||
Water Segment Revenue — U.S.($M)1 | 31.3 | 29.6 | 26.4 | 23.7 | 28.1 | 26.1 | 23.5 | 22 | 26.7 | 24.5 | 22.2 | 19.9 | |
Water U.S. Organic Revenue Growth(%) | 11.5% | 13.5% | 12.3% | 7.4% | 5.2% | 6.7% | 5.9% | 10.6% | 7.2% | ||||
Water Segment Revenue — International($M)2 | 27.5 | 28.9 | 23.9 | 26.9 | 26.2 | 24.9 | 21.8 | 23.1 | 23.5 | 22.3 | 20.9 | 21.9 | |
Water International Organic Revenue Growth(%) | 3.9% | 12.4% | 1.9% | 11.5% | 8.9% | 10.2% | 8.9% | 7.4% | 3.2% | ||||
Water International Currency Impact(%) | 1.1% | 3.8% | 7.5% | 4.7% | 2.7% | 1.7% | -4.4% | -1.7% | 2.3% | ||||
Water Segment Gross Profit($M)1 | 42.7 | 43.6 | 36.5 | 33.6 | 38.1 | 35.5 | 32.1 | 32.7 | 34.8 | 32.1 | 30.5 | ||
Water Segment Gross Margin(%) | 72.6% | 74.4% | 72.7% | 70.1% | 69.6% | 70.8% | 69.3% | 68.6% | 70.8% | ||||
Water Segment Operating Income($M)1 | 29.6 | 30.3 | 23.7 | 26.4 | 24.6 | 20.8 | 23.6 | 20.5 | 19.4 | 17.2 | |||
Water Segment Operating Margin(%) | 50.3% | 51.7% | 47.1% | 48.6% | 48.3% | 45.9% | 47.1% | 43.9% | 45.1% | ||||
Livestock, Poultry & Dairy (LPD) Segment Revenue($M)7 | 34.8 | 35.2 | 32.5 | 37.5 | 33.9 | 31.8 | 28.6 | 34.6 | 29 | 30.3 | 28.2 | 32.8 | |
LPD Segment Organic Revenue Growth(%) | 3.0% | 9.0% | 7.2% | 4.0% | 14.2% | 2.6% | 4.2% | 7.1% | -3.8% | ||||
LPD Segment Reported Revenue Growth(%) | 2.6% | 10.8% | 13.6% | 8.5% | 17.1% | 4.8% | 1.4% | 5.4% | -1.8% | ||||
LPD Segment Currency Impact(%) | -0.4% | 1.8% | 6.4% | 4.5% | 2.9% | 2.2% | -2.8% | -1.7% | 2.0% | ||||
LPD Segment Revenue — U.S.($M)1 | 7.70 | 6.60 | 6.40 | 7 | 6.90 | 5.80 | 5.80 | 6.40 | 5.60 | 5.10 | 5.20 | 5 | |
LPD U.S. Organic Revenue Growth(%) | 11.5% | 14.6% | 10.3% | 9.8% | 23.4% | 12.8% | 12.1% | 29.4% | 8.2% | ||||
LPD Segment Revenue — International($M)2 | 27.2 | 28.6 | 26.1 | 30.4 | 27.1 | 26 | 22.8 | 28.1 | 23.4 | 25.2 | 23 | 27.8 | |
LPD International Organic Revenue Growth(%) | 0.8% | 7.8% | 6.5% | 2.7% | 12.1% | 0.6% | 2.4% | 3.0% | -5.7% | ||||
LPD International Currency Impact(%) | -0.5% | 2.1% | 7.9% | 5.4% | 3.5% | 2.6% | -3.4% | -1.9% | 2.3% | ||||
LPD Segment Gross Profit($M)1 | 18.3 | 18.7 | 16.9 | 19 | 15.9 | 14.9 | 14.4 | 17.1 | 14.6 | 15.6 | 15.2 | ||
LPD Segment Gross Margin(%) | 52.6% | 53.0% | 52.1% | 47.0% | 47.0% | 50.2% | 50.5% | 51.3% | 54.0% | ||||
LPD Segment Operating Income($M)1 | 1.90 | 2.40 | 1.30 | 0.50 | -0.50 | 0.10 | 0.90 | 1.50 | 0.90 | 4.30 | |||
LPD Segment Operating Margin(%) | 5.5% | 6.9% | 4.0% | 1.4% | -1.6% | 0.4% | 3.1% | 4.9% | 3.1% | ||||
Other Segment Revenue (OPTI Medical Human Point-of-Care Diagnostics)($M)4 | 4.60 | 4.60 | 4 | 4.10 | 4.50 | 4.30 | 4.70 | 4.10 | 4.40 | 4.20 | 3.50 | 5.80 | |
Other Segment Organic Revenue Growth(%) | 3.2% | 8.3% | -14.0% | -0.4% | 1.5% | 0.1% | 32.2% | -28.6% | -21.4% | ||||
Other Segment Reported Revenue Growth(%) | 3.2% | 8.3% | -14.0% | -0.4% | 1.5% | 0.1% | 32.2% | -28.6% | -21.4% | ||||
Other Segment Gross Profit($M)1 | 1.90 | 1.10 | 1.80 | 1.90 | 2.20 | 2.10 | 2.20 | 2.50 | 1.10 | ||||
Other Segment Gross Margin(%) | 41.9% | 22.8% | 44.4% | 42.5% | 51.5% | 45.3% | 49.9% | 57.8% | 31.2% | ||||
Other Segment Operating Income($M)1 | 1.40 | -0.40 | 0.10 | -0.50 | 0.40 | 0.40 | 2.30 | 0.20 | -1 | 1.60 | |||
Other Segment Operating Margin(%) | 29.8% | -8.7% | 1.8% | -11.4% | 10.2% | 9.3% | 52.6% | 5.8% | -29.3% | ||||
Total Consolidated Organic Revenue Growth(%)8 | 10.0% | 9.0% | 11.2% | 12.2% | 12.0% | 9.3% | 4.7% | 5.8% | 7.8% | ||||
Total Consolidated Reported Revenue Growth(%) | 9.9% | 9.7% | 14.3% | 14.3% | 13.3% | 10.6% | 3.6% | 5.8% | 8.8% | ||||
Total Consolidated Currency Impact(%) | -0.2% | 0.7% | 3.1% | 2.0% | 1.3% | 1.2% | -1.2% | -0.4% | 1.0% | ||||
Total U.S. Organic Revenue Growth(%) | 8.6% | 7.7% | 10.7% | 11.8% | 10.5% | 8.7% | 3.6% | 4.1% | 7.3% | ||||
Total International Organic Revenue Growth(%) | 12.4% | 11.2% | 11.9% | 13.0% | 14.6% | 10.5% | 6.8% | 8.8% | 8.7% | ||||
Non-GAAP Comparable Operating Profit($M) | 398 | 420 | 353 | 306 | 355 | 373 | 308 | 262 | 304 | ||||
Non-GAAP Comparable Operating Margin(%) | 32.7% | 34.7% | 31.8% | 28.6% | 32.1% | 33.6% | 30.8% | 27.4% | 31.2% | ||||
Non-GAAP Comparable Gross Margin(%) | 62.7% | 63.9% | 63.3% | 60.4% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% | ||||
Non-GAAP Comparable Diluted EPS($) | 3.96 | 4.07 | 3.30 | 2.92 | 3.24 | 3.53 | 2.87 | 2.49 | 2.79 | ||||
Full-Year Revenue Guidance Range6 | |||||||||||||
Full-Year Revenue Guidance — Low($M) | 4,741 | 4,700 | 4,675 | 4,632 | 4,270 | 4,205 | 4,095 | 4,055 | 3,930 | ||||
Full-Year Revenue Guidance — High($M) | 4,767 | 4,745 | 4,760 | 4,720 | 4,300 | 4,280 | 4,210 | 4,170 | 4,040 | ||||
Full-Year Organic Revenue Growth Guidance — Low(%) | 9.3% | 8.5% | 7.7% | 7.0% | 8.8% | 7.0% | 6.0% | 6.0% | 7.0% | ||||
Full-Year Organic Revenue Growth Guidance — High(%) | 10.0% | 9.7% | 9.7% | 9.0% | 9.5% | 9.0% | 9.0% | 9.0% | 10.0% | ||||
Full-Year Reported Revenue Growth Guidance — Low(%) | 10.1% | 9.1% | 8.6% | 7.6% | 9.6% | 7.7% | 5.0% | 4.0% | 7.5% | ||||
Full-Year Reported Revenue Growth Guidance — High(%) | 10.8% | 10.3% | 10.6% | 9.6% | 10.3% | 9.7% | 8.0% | 7.0% | 10.5% | ||||
Full-Year CAG Diagnostics Recurring Growth Guidance Range4 | |||||||||||||
CAG Diagnostics Recurring Organic Growth Guidance — Low(%) | 10.3% | 9.5% | 8.7% | 8.0% | 7.5% | 5.8% | 5.0% | 5.0% | 7.5% | ||||
CAG Diagnostics Recurring Organic Growth Guidance — High(%) | 11.0% | 10.7% | 10.7% | 10.0% | 8.2% | 8.0% | 8.0% | 8.0% | 10.5% | ||||
CAG Diagnostics Recurring Reported Growth Guidance — Low(%) | 11.0% | 10.1% | 9.6% | 8.6% | 8.3% | 6.5% | 4.0% | 3.0% | 7.5% | ||||
CAG Diagnostics Recurring Reported Growth Guidance — High(%) | 11.7% | 11.3% | 11.6% | 10.6% | 9.0% | 8.7% | 7.0% | 6.0% | 10.5% | ||||
Full-Year Margin, EPS, CapEx & Free Cash Flow Conversion Guidance7 | |||||||||||||
Full-Year Operating Margin Guidance — Low(%) | 32.1% | 32.3% | 32.1% | 32.0% | 31.6% | 31.3% | 31.1% | 31.0% | 30.2% | ||||
Full-Year Operating Margin Guidance — High(%) | 32.3% | 32.5% | 32.5% | 32.5% | 31.8% | 31.6% | 31.6% | 31.5% | 30.7% | ||||
Full-Year Diluted EPS Guidance — Low($) | 14.96 | 14.69 | 14.45 | 14.29 | 12.81 | 12.40 | 11.93 | 11.74 | 10.84 | ||||
Full-Year Diluted EPS Guidance — High($) | 15.16 | 14.94 | 14.90 | 14.80 | 13.01 | 12.76 | 12.43 | 12.24 | 11.33 | ||||
Full-Year Capital Expenditures Guidance($M) | 160 | 180 | 180 | 180 | 140 | 160 | 160 | 160 | 180 | ||||
Full-Year Free Cash Flow Conversion Guidance (% of Net Income) — Low(%) | 95.0% | 90.0% | 85.0% | 85.0% | 95.0% | 80.0% | 80.0% | ||||||
Full-Year Free Cash Flow Conversion Guidance (% of Net Income) — High(%) | 100.0% | 100.0% | 95.0% | 95.0% | 100.0% | 85.0% | 85.0% | ||||||
Days Sales Outstanding (DSO)(ngày) | 47 | 46 | 46 | 47 | 47 | 45 | 46 | 47 | 49 | 47 | 46 | 46 | |
Inventory Turns(×) | 1.50 | 1.40 | 1.40 | 1.60 | 1.50 | 1.50 | 1.30 | 1.30 | 1.30 | 1.40 | 1.30 | 1.30 | |
Inventory Breakdown by Production Stage3 | |||||||||||||
Finished Goods Inventory($M) | 249 | 252 | 250 | 249 | 255 | 253 | 256 | 246 | 251 | 244 | 259 | 245 | |
Raw Materials Inventory($M) | 106 | 105 | 98.4 | 96.3 | 103 | 104 | 105 | 104 | 107 | 104 | 103 | 106 | |
Work-in-Process Inventory($M) | 35.9 | 35.5 | 34.1 | 32.6 | 34 | 35.1 | 35 | 31.9 | 32.4 | 32 | 28.2 | 29 | |
Share Repurchase Activity (Monthly & Quarterly)1 | |||||||||||||
Quarterly Open-Market Shares Repurchased (Thousands)2 | 199.00 | 582.00 | 588.00 | 356.00 | 411.00 | 713.00 | 931.00 | 564.00 | 459.00 | 415.00 | 303.00 | 90.00 | |
Quarterly Open-Market Share Repurchase Cost($M) | 112 | 332 | 361 | 242 | 242 | 328 | 409 | 249 | 225 | 208 | 167 | 34.6 | |
Quarterly Average Price Paid per Share (Open Market)($) | 563 | 571 | 614 | 680 | 588 | 459 | 440 | 441 | 490 | 501 | 551 | 420 | |
Operating Lease Undiscounted Future Payments — Total($M)7 | 143 | 146 | 145 | 148 | 154 | 155 | 139 | 140 | 147 | 145 | 145 | 141 | |
Operating Lease Payments Due — Year 1($M) | 32.8 | 31.7 | 30.3 | 32.1 | 34.2 | 32.7 | 27.8 | 26.4 | 28.4 | 26.3 | 25.2 | 24.2 | |
Operating Lease Payments Due — Year 2($M) | 28.4 | 27 | 24.5 | 29.8 | 29.1 | 27.3 | 22.4 | 26.5 | 26.2 | 24.4 | 23.1 | 23.5 | |
Operating Lease Payments Due — Year 3($M) | 23.5 | 22.2 | 19.6 | 23.6 | 22.8 | 21 | 16.3 | 21.1 | 20.7 | 19.6 | 18.2 | 21 | |
Operating Lease Payments Due — Year 4($M) | 15.5 | 14.7 | 12.4 | 18.6 | 18.1 | 16.9 | 12.8 | 15.1 | 14.8 | 13.9 | 13.1 | 16.1 | |
Operating Lease Imputed Interest($M) | 18.6 | 19.1 | 19.7 | 19.2 | 20.3 | 21.6 | 20.2 | 20.7 | 22.4 | 21.9 | 22.2 | 21.1 | |
Operating Cash Outflows from Operating Leases($M) | 9.20 | 8.60 | 8.40 | 8.60 | 8.70 | 8.50 | 7.60 | 6.50 | 7.70 | 6.50 | 7.20 | 7.20 | |
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M) | 4.70 | 9.10 | 5.70 | 2.70 | 6.10 | 18 | 4.60 | 3.70 | 5.20 | 5.60 | 11.5 | 1.20 | |
Confirmed Supplier Finance Program Obligations Outstanding($M) | 6.20 | 7 | 6.80 | 6.20 | 7.20 | 7.20 | 8.70 | 6 | 5.50 | 8.70 | 10.4 | 9.10 | |
Unrecognized Stock-Based Compensation Cost($M) | 90.7 | 105 | 120 | 67.3 | 80.9 | 94.7 | 108 | 63.8 | 81 | 95.6 | 107 | 60.2 | |
Peer Benchmark: Zoetis Inc. (ZTS) — Consolidated Revenue($M) | 2,391 | 2,468 | 2,262 | 2,373 | 2,422 | 2,474 | 2,198 | 2,317 | 2,388 | 2,361 | 2,190 | 2,213 | |
Peer Benchmark: Elanco Animal Health (ELAN) — Consolidated Revenue($M) | 1,265 | 1,368 | 1,371 | 1,144 | 1,137 | 1,241 | 1,193 | 1,020 | 1,030 | 1,184 | 1,205 | 1,035 | |
Consolidated Revenue($M)8 | 1,214 | 1,217 | 1,141 | 1,091 | 1,105 | 1,110 | 998 | 954 | 976 | 1,004 | 964 | 902 | |
Consolidated Gross Profit($M) | 764 | 779 | 723 | 658 | 683 | 695 | 623 | 571 | 596 | 619 | 593 | 526 | |
Research & Development Expense($M) | 68.8 | 65.4 | 65.8 | 66.8 | 63.4 | 61.9 | 59.1 | 57.7 | 54 | 55.4 | 52.6 | 51.8 | |
Sales & Marketing Expense($M) | 170 | 171 | 175 | 167 | 159 | 161 | 156 | 150 | 146 | 143 | 150 | 142 | |
General & Administrative Expense($M) | 123 | 117 | 119 | 109 | 106 | 98.7 | 91.6 | 101 | 91.9 | 157 | 92 | 87 | |
Consolidated Operating Income($M) | 402 | 426 | 363 | 316 | 355 | 373 | 317 | 262 | 304 | 264 | 299 | 245 | |
Consolidated Net Income($M) | 317 | 338 | 278 | 248 | 275 | 294 | 243 | 216 | 233 | 203 | 236 | 195 | |
GAAP Diluted Earnings per Share($) | 4.01 | 4.27 | 3.47 | 3.40 | 3.63 | 2.96 | 2.80 | 2.44 | 2.81 | ||||
Weighted-Average Diluted Shares(M) | 79.1 | 79.3 | 80.2 | 80.7 | 81.0 | 81.9 | 83.1 | 83.4 | 84.0 | ||||
Selected Balance Sheet Items10 | |||||||||||||
Cash & Cash Equivalents($M) | 198 | 197 | 201 | 180 | 208 | 165 | 164 | 288 | 309 | 402 | 397 | 454 | |
Accounts Receivable, Net($M) | 616 | 627 | 604 | 552 | 567 | 561 | 528 | 474 | 511 | 534 | 507 | 457 | |
Total Inventories($M) | 391 | 392 | 382 | 378 | 392 | 393 | 396 | 382 | 390 | 380 | 391 | 380 | |
Property, Plant & Equipment, Net($M) | 732 | 733 | 740 | 747 | 739 | 740 | 718 | 713 | 718 | 708 | 709 | 702 | |
Operating Lease Right-of-Use Assets($M) | 120 | 123 | 121 | 123 | 128 | 130 | 116 | 116 | 121 | 120 | 120 | 116 | |
Goodwill($M) | 641 | 411 | 412 | 414 | 414 | 415 | 408 | 405 | 412 | 408 | 409 | 366 | |
Other Intangible Assets, Net($M) | 118 | 98.2 | 105 | 110 | 115 | 104 | 107 | 112 | 107 | 111 | 115 | 84.5 | |
Total Assets($M) | 3,707 | 3,442 | 3,386 | 3,351 | 3,387 | 3,331 | 3,214 | 3,293 | 3,351 | 3,415 | 3,354 | 3,260 | |
Total Stockholders' Equity($M) | 1,869 | 1,613 | 1,556 | 1,605 | 1,561 | 1,459 | 1,448 | 1,595 | 1,618 | 1,580 | 1,569 | 1,485 | |
Common Shares Outstanding(M) | 78.8 | 78.9 | 79.2 | 79.7 | 80 | 80.2 | 80.7 | 81.6 | 82.0 | 82.5 | 82.9 | 83.0 | |
Selected Cash Flow Items5 | |||||||||||||
Operating Cash Flow($M) | 450 | 347 | 266 | 356 | 402 | 186 | 238 | 262 | 220 | 248 | 199 | 250 | |
Capital Expenditures (Purchases of Property & Equipment)($M) | 28.9 | 24.6 | 32 | 29.4 | 31.1 | 34.1 | 30 | 29.3 | 28.1 | 33.3 | 30.3 | 32.6 | |
Depreciation & Amortization($M) | 40.6 | 41.1 | 37.7 | 38.7 | 36.6 | 35.8 | 34.1 | 33.7 | 34.1 | 32.2 | 29.9 | 29.7 | |
Stock-Based Compensation Expense($M) | 16.2 | 16.1 | 16.3 | 16.1 | 14.4 | 14.9 | 14.6 | 14.3 | 15.9 | 15.7 | 14.4 | 15.2 | |
Cash Paid for Repurchases of Common Stock($M) | 112 | 347 | 351 | 238 | 240 | 338 | 401 | 246 | 221 | 216 | 155 | 36.9 | |
16 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- All operational and financial figures are reported directly as published by IDEXX Laboratories, Inc., the U.S. Bureau of Labor Statistics, or peer SEC filings; the only derived cells are quarterly splits from cumulative year-to-date or full-year filings.
- IDEXX's fiscal year ends December 31; quarterly periods Q1, Q2, Q3, and Q4 end March 31, June 30, September 30, and December 31, respectively.
- Remaining performance obligations (RPO) under multi-year customer commitment arrangements (such as IDEXX 360) are disclosed in billions of dollars in Note 3 ($5.3B as of Q3 2026) and presented in millions ($5,300M) for unit consistency.
Không hiện vì thiếu các kỳ gần đây (11)
- CAG Diagnostics Customer Retention Rate — Disclosed qualitatively as 'high-nineties' or as a lower bound (>97% at Investor Day), without exact point time-series values.
- IDEXX Cancer Dx Ordering Veterinary Practices — Disclosed only as intermittent cumulative launch milestones or bounds ('nearly 5,000' in Q3 2025, 'nearly 6,000' in Q4 2025).
- Global Commercial Reference Laboratories Count — Disclosed only as lower bounds ('more than 80' global, 'over 50' U.S., 'more than 25' international in Form 10-K).
- SNAP Pro Analyzer Placements — Discontinued from quarterly Earnings Snapshot placement tables after Q1 2020 following transition to premium analyzer reporting.
- IDEXX inVue Dx Installed Base YoY Growth (%) — Product launched commercially in Q1 2025; only 1 year-over-year quarterly growth observation (Q3 2026: +147%) published to date.
- U.S. EEO-1 Consolidated Workforce Headcount (6,822 in FY2024; 6,818 in FY2023) — Excluded because the FY2025 EEO-1 report has not yet been published.
- IDEXX Laboratorios, S.L. (Spain) Statutory Revenue & FTEs ($71.15M revenue, $2.38M pretax profit, 199 FTEs in FY2025 EU Public Country-by-Country Report) — Excluded because only a single fiscal year (FY2025) has been published under EU Directive 2021/2101.
- Global Workforce Gender Representation (59% women overall, 50% management, 59% STEM in FY2025) — Excluded where text layout prevented complete verbatim multi-year verification across all three annual reports.
- Investor Day Point-in-Time Survey & Operational Metrics (Brand NPS of 57, 260 reference lab pathologists, 99.99% sample processing accuracy) — Disclosed only as one-off Investor Day snapshots rather than recurring periodic series.
- Reagent Rental & Instrument Lease Economics › Instruments Transferred from Inventory to PP&E for Operating Reagent Rentals — Excluded due to fewer than 3 consecutive recent quarters or 2 consecutive completed fiscal years.
- Unconditional Purchase Obligations Due within 1 Year — Excluded due to fewer than 3 consecutive recent quarters or 2 consecutive completed fiscal years.
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Companion Animal Diagnostics: Instrument Placements, Installed Base & U.S. Practice Trends
CAG Disaggregated Modality Revenue & Organic Growth Bridges
Commercial Backlog (RPO), IDEXX 360 Customer Commitments & Reagent Rental Economics
- Remaining Performance Obligations — Multi-Year Customer Commitment Arrangements ($M)12 kỳ
- Remaining Performance Obligations — Reagent Rental Arrangements ($M)12 kỳ
- Remaining Performance Obligations — Extended Warranties (>1 Year) ($M)29 kỳ
- Contract Assets under Customer Commitment Arrangements ($M)24 kỳ
- Capitalized Upfront Customer Incentives & IDEXX Points ($M)11 kỳ
- Contract Liabilities & Deferred Extended Warranty / Software PCS Revenue ($M)0 kỳ
- Capitalized Incremental Customer Commitment Sales Commissions ($M)33 kỳ
- Reagent Rental & Instrument Lease Economics ($M)0 kỳ
Water, Livestock/Poultry/Dairy (LPD), Human Point-of-Care & Segment Profitability
Full-Year Management Financial & Operational Guidance (As Issued Each Quarter)
Working Capital Efficiency, Inventory Breakdown, Leases, PP&E & Share Repurchases
- Days Sales Outstanding (DSO) (ngày)37 kỳ
- Inventory Turns (×)37 kỳ
- Return on Invested Capital, Excluding Cash & Marketable Securities (ROIC) (%)3 kỳ
- Inventory Breakdown by Production Stage ($M)0 kỳ
- Share Repurchase Activity (Monthly & Quarterly)0 kỳ
- Gross Property, Plant & Equipment by Asset Class ($M)2 kỳ
- Operating Lease Undiscounted Future Payments — Total ($M)31 kỳ
- Confirmed Supplier Finance Program Obligations Outstanding ($M)20 kỳ
- Unrecognized Stock-Based Compensation Cost ($M)43 kỳ
Workforce, Workplace Safety, Product Quality (SASB HC-MS), Environment & Governance
- Total Regular Full-Time & Part-Time Employees6 kỳ
- Product Safety & Regulatory Compliance (SASB HC-MS-250a)0 kỳ
- Total Scope 1 & 2 Greenhouse Gas Emissions (MT CO2e)5 kỳ
- Total Global Energy Consumption (MWh)5 kỳ
- Global Water Consumption (Cubic Meters)5 kỳ
- Board of Directors Independence & Composition (%)0 kỳ
U.S. Veterinary & Diagnostics Macro Benchmarks (BLS Monthly) & Animal Health Peers
- U.S. CPI-U: Veterinarian Services (SA, 1982–84=100) (×)104 kỳ
- U.S. PPI: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) (×)105 kỳ
- U.S. All Employees: Veterinary Services (NAICS 541940, SA, Thousands)105 kỳ
- Peer Benchmark: Zoetis Inc. (ZTS) — Consolidated Revenue ($M)43 kỳ
- Peer Benchmark: Elanco Animal Health (ELAN) — Consolidated Revenue ($M)39 kỳ
Geographic Revenue Disaggregation & Long-Lived Assets by Country (SEC Filings)
Consolidated Financial Context (GAAP Financial Statements)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của IDEXX Laboratories
- Form 8-K Ex. 99.1 (2026-11-02) ↗
- Form 10-K (FY2025, filed 2026-02-20) ↗
- Form 8-K Ex. 99.1 (2026-02-02) ↗
- Form 10-Q (FY2026Q3, filed 2026-11-02) ↗
- Form 10-Q (2026-11-02) ↗
- Form 10-K (2026-02-20) ↗
- IDEXX 2025 Corporate Responsibility Report ↗
- IDEXX Q3 2026 Earnings Snapshot ↗
- U.S. Bureau of Labor Statistics — CPI-U Veterinarian Services (SA, Series CUSR0000SS62031) ↗
- U.S. Bureau of Labor Statistics — PPI In-Vitro Diagnostic Substance Manufacturing (NAICS 325413, Series PCU325413325413) ↗
- U.S. Bureau of Labor Statistics — All Employees: Veterinary Services (NAICS 541940, SA, Series CES6054194001) ↗
- Zoetis Inc. (ZTS) Form 10-Q (2026-11-05) ↗
See a number that looks wrong?